摘要
维生素K是活性凝血因子Ⅱ、Ⅶ、Ⅺ和Ⅹ形成所必需的物质,缺乏维生素K会使凝血时间延长。美国ARYx Therapeutics公司在研新药维生素K拮抗剂Tecarfarin作为新一代口服抗凝血剂,用于治疗心房颤动、心脏瓣膜病和深静脉血栓。已经公布的Ⅱ和Ⅲ期临床试验数据显示,Tecarfarin的疗效与华法林具有可比性,并可能减少更多的药物与食物或药物之间的相互作用。目前该公司所做的临床试验已经得到美国食品药品监督管理局(FDA)的书面确认。
Vitamin K is required to form the active clotting factors Ⅱ, Ⅻ, Ⅺ, and Ⅹ. Lacking of vitamin K could cause to extend blood coagulation time. The United States ARYx Therapeutics Company researched new drug, Tecarfarin that is one of vitamin K antagonists as a new generation of oral anticoagulant therapy and can be used in the treatment of atrial fibrillation （af）, heart valve disease, and deep vein thrombosis. It is based on the published Ⅱand Ⅲphase of clinical trial to show that it has no less than Warfarin theropy result and may reduce the more medicine-food interactions. At present what the company does in clinical experiment has been received from the U.S. food and drug administration （FDA） written confirmation.
出处
《现代药物与临床》
CAS
2012年第1期38-42,共5页
Drugs & Clinic
基金
国家重大新药创制专项(2011ZX09401-009
2010ZX09401-307-1-1)
